Angle Ovarian Cancer Testing Platform Study Enrols First Patients

(Alliance News) - Liquid biopsy firm Angle PLC said Thursday the first patients for its ovarian cancer test study have been enrolled ahead of anticipated completion early in 2020.

The study of 200 patients is the main phase of its ovarian cancer clinical verification study being undertaken by the University of Rochester Medical Center Wilmot Cancer Institute in the US. The study is examining the use of Angle's Parsortix and HyCEAD Ziplex platforms as a simple blood test to detect ovarian cancer.

A positive outcome of the study - due to complete in the first quarter of 2020 - will support the plans of Angle to launch a clinical assay for ovarian cancer.

"We are excited about the start of the full clinical verification study to demonstrate the performance of our ovarian cancer test designed to support the launch of a clinical assay at a clinical laboratory and/or via a commercial partnership," Angle Chief Executive Officer Andrew Newland said.

Shares in Angle were 1.3% lower at 68.12 pence in London on Thursday.